LC–MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.7K citations

Pharmacy, Oncology, Pharmacology +17

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

Medicine, Oncology, Pharmacology +17

Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing

Hans K. Erickson, Peter U. Park, Wayne C. Widdison et al. · Cancer Research · 2006 · 574 citations · Full text

Medicine, Oncology, Pharmacology +14

Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer

Wayne C. Widdison, Sharon Wilhelm, Emily E. Cavanagh et al. · Journal of Medicinal Chemistry · 2006 · 311 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Sandhya Girish, Manish Gupta, Bei Wang et al. · Cancer Chemotherapy and Pharmacology · 2012 · 265 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17